Medpace Holdings Inc vs United Microelectronics Corp — how do they compare? Medpace Holdings Inc trades at $596 (market cap $16.90B), while United Microelectronics Corp trades at $19.31 (market cap $47.81B). The key difference: United Microelectronics Corp is far larger — about 2.8× Medpace Holdings Inc's market cap, and United Microelectronics Corp pays a 2.12% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | UMC | |
|---|---|---|
Market Cap | $16.90B | $47.81B |
Sector | Technology | Technology |
52-Week High | $620.59 | $28.02 |
52-Week Low | $393.42 | $6.58 |
Enterprise Value | $16.52B | $44.93B |
Dividend Yield | — | 2.12% |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
UMC trades at $19.50, up 3.78% today, with neutral technical signals and strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.54 significantly exceeding the $0.16 expectation. Recent announcements include fab expansions in Singapore and Taiwan to meet AI-driven demand, supported by growing silicon photonics production. Valuation metrics show a P/E of 18.55 and P/S of 6.02, with robust profitability margins including 32.75% net income margin.
Outlook remains positive with projected revenue growth to $250.7B in 2026 and net income rebound to $82.1B. Key risks include semiconductor cycle volatility and execution challenges from capacity expansion. Analyst consensus shows mixed sentiment with 26.7% buy ratings versus 20% sell recommendations, suggesting cautious optimism amid expansion initiatives.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →